Content Spotlight
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
October 2, 2023
AbbVie will end its CD47 partnership, returning all rights for the drug, according to Shanghai’s I-Mab.
In 2020, AbbVie acquired ex-China rights to anti-CD47 monoclonal antibody lemzoparlimab (TJC4) in a deal worth up to $2 billion, including options on two other I-Mab candidates. I-Mab will keep $200 million in AbbVie upfront and milestone payments.
AbbVie said the breakup was a “strategic decision,” a description that was not explained, though the company has ended several partnerships recently. A year ago, AbbVie reduced the scope of the I-Med partnership, stopping two Phase Ib trials of lemzoparlimab, one in myelodysplastic syndrome (MDS) and the other in acute myeloid leukemia.
DepositPhotos/Piter2121
I-Mab is not the only China company to find itself with global rights to a lead drug after signing a big-dollar out-licensing for the candidate. A week earlier, Novartis ended a $2.2 billion Global partnership with BeiGene for its PD-1 drug.
As a result, I-Mab will regain the global rights to develop and commercialize all CD47 compounds covered by the deal, including the only named candidate, lemzoparlimab. The company is currently conducting a China Phase III registrational study of lemzoparlimab in combination with azacitidine as a first-line therapy in patients with higher-risk myelodysplastic syndrome.
In 2022, I-Mab announced that lemzoparlimab showed encouraging results in a China Phase II trial for the MDS indication. Lemzoparlimab was administered in combination with azacytidine, an AbbVie approved drug. After six months of treatment with lemzoparlimab-azacytidine, the overall response rate (ORR) was 87% and complete response rate (CRR) was 40%
AbbVie and I-Mab announced their global agreement in September 2020. For an upfront payment of $180 million and the promise of up to $1.74 billion in success-based milestones, AbbVie earned exclusive rights (ex-China) to develop and commercialize lemzoparlimab. The deal also allowed for potential future targets using other I-Mab CD47 molecules.
In August 2022, AbbVie scaled the partnership back. Although the partners did not disclose the reason for ending the two trials, I-Mab said the decision was not triggered by “specific or unexpected safety concerns.” I-Mab said the partnership could still deliver up to $1.3 billion in development, regulatory and sales milestones.
If approved for China use, lemzoparlimab could become a first-in-class CD47 antibody for hematologic malignancies in China, according to I-Mab. Lemzoparlimab is a novel CD47 antibody designed to offer better drug safety without compromising efficacy. I-Mab is currently conducting a China Phase III registrational study of lemzoparlimab in combination with azacitidine (AZA) as a first-line treatment of patients with higher-risk myelodysplastic syndrome.
For AbbVie, renouncing the I-Mab partnership follows soon after it announced that it would not exercise its exclusive licensing option for Harpoon Therapeutics’ TriTAC candidate HPN217, which is in a Phase I trial for multiple myeloma. And, in August, AbbVie also ended development of two early-stage oncology candidates from its developmental pipeline: ABBV-011, an anti-SEZ6 antibody-drug conjugate in clinical trials for relapsed or refractory lung cancer; and ABBV-647, a Pfizer-partnered ADC targeting the PTK7 protein to treat solid tumors.
In an SEC filing, I-Mab said, “Lemzoparlimab has the potential to be the first-in-class CD47 antibody for hematologic malignancies in China, The company will continue to review follow-up data from the Phase II study of lemzoparlimab in HR-MDS, as well as all available and upcoming data from other investigational CD47 therapies, to explore future development opportunities with lemzoparlimab.”
I-Mab’s pipeline consists of more than 10 clinical and pre-clinical stage drug candidates driven by its Fast-to-Proof-of-Concept and Fast-to-Market development programs through internal R&D and global partnerships and commercial partnerships. I-Mab has established its global footprint in Shanghai, Hangzhou, Guangzhou and Hong Kong in China, and Maryland and San Diego in the US.
A version of this article was first published in ChinaBio Today on September 25, 2023
You May Also Like